Adults with YOD have excess hospitalizations across their lifespan compared with persons with usual-onset T2D, including an unexpectedly large burden of mental illness in young adulthood. Efforts to prevent YOD and intensify cardiometabolic risk factor control while focusing on mental health are urgently needed (Annals of Internal Medicine)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers
The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes is updated and published annually in a supplement to the January issue of Diabetes Care
Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin
In T2D treatment, the use of acarbose as an add-on remedy to metformin was associated with lower risks of major atherosclerotic events, ischemic stroke, and hypoglycemia compared with the use of sulfonylurea as an add-on remedy (Journal of Clinical Endocrinology & Metabolism)
Predicting Progression to Type 1 Diabetes from Ages 3 to 6 in Islet Autoantibody Positive TEDDY Children
This study highlights the application of precision medicine techniques to predict progression to diabetes over a 3‐year window in TEDDY subjects. This multifaceted model provides preliminary improvement in prediction over simpler prediction tools. Additional tools are needed to maximize the predictive value of these approaches (Pediatric Diabetes)
National Diabetes Transition Audit, 2011 – 2017
This is the second published report for the NDTA and contains linked data from the NPDA and NDA for the audit period 2011-12 to 2016-17. The report focuses on young people with Type 1 diabetes (NHS Digital)
Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue
Results suggest that insulin bolus delivery with fast delivery speed may result in more rapid insulin absorption and, thus, may provide a better control of meal-related glucose excursions than that obtained with bolus delivery using slow delivery speeds. Our findings may have important implications for the future design of the bolus delivery unit of insulin pumps (Diabetes Technology and Therapeutics)
Relationship between HbA1c and all-cause mortality in older patients with insulin-treated type 2 diabetes: results of a large UK Cohort Study
Both low and high HbA1c were associated with increased all-cause mortality, among older patients with insulin-treated T2D. This cohort study supports the need for individualisation of care and suggests better outcomes with HbA1c levels around 6.5–7.4% and markedly excess risk with HbA1c > 11% (Age and Ageing)
A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes
The variant rs8192675 in the SLC2A2 gene (C allele) is associated with an improved glucose response to metformin monotherapy during the first year after diagnosis in type 2 diabetes (Diabetologia)
Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis
Despite the financial and human resources involved and the relevance for therapeutic guidelines and clinical decisions, about one-third of phase III clinical trials on diabetic nephropathy remain unpublished. Interventions used in published trials showed a low efficacy on renal outcome (Diabetes Therapy)
Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial
This study indicates that dapagliflozin in T2DM patients can decrease the levels of urinary proximal tubular injury biomarkers, thus highlighting its renoprotective effect. SGLT2 inhibitors could prove useful in treating T2DM by protecting against renal tubular injury and may lead to reduced long-term renal outcomes (Clinical Kidney Journal)
Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up‐titration in treatment of patients with type 2 diabetes: the CompoSIT‐M Study
In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose up‐titration improved glycemic response and HbA1c goal attainment with similar safety and tolerability compared to metformin up‐titration alone (Diabetes, Obesity and Metabolism)
Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide
The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways (Diabetologia)
Cardiovascular outcome trials of glucose-lowering medications: an update
In summary, taking into account the findings from these new studies, it is suggested that a GLP-1RA should be offered to all people with CVD and type 2 diabetes, and SGLT2 inhibitors should be prescribed for those at high risk of heart failure or with progressive decline in eGFR. DPP4 inhibitors are a safe choice within the glucose-lowering stepped algorithm (Diabetologia)
Prevalence of diabetes and its effects on stroke outcomes: A meta‐analysis and literature review
Approximately one‐third of all stroke patients have diabetes. Uniform methods to screen for diabetes after stroke are required to identify individuals with diabetes to design interventions aimed at reducing poor outcomes in this high‐risk population (Journal of Diabetes Investigation)
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study
In this study of middle-aged patients with type 2 diabetes and relatively low fracture risk, canagliflozin was not associated with increased risk for fracture compared with GLP-1 agonists (Annals of Internal Medicine)
Prevention and reversal of Type 2 diabetes: highlights from a symposium at the 2018 Diabetes UK Annual Professional Conference
Effective prevention and long term reversal of Type 2 diabetes is feasible. The impact upon the individual must be considered during delivery of advice and support (Diabetic Medicine)
Experiences of women, hospital clinicians and general practitioners with gestational diabetes mellitus postnatal follow-up: A mixed methods approach
This research informs seven practical recommendations to help promote completion of recommended postnatal GDM follow-up (Diabetes Research and Clinical Practice)
Behavioral Strategies to Lower Postprandial Glucose in Those with Type 2 Diabetes May Also Lower Risk of Coronary Heart Disease
These secondary analyses suggest that broad-spectrum lifestyle interventions that focus on lowering PPG may lower the risk of future CHD, which could guide future research (Diabetes Therapy)
A Multinational Observational Study Assessing Insulin Use: Understanding the Determinants Associated with Progression of Therapy
Among insulin‐treated patients with T2D, treatment changes were common; however only approximately one‐fourth of individuals achieved their HbA1c target (Dibetes, Obesity and Metabolism)
Cost‐effectiveness of intensification with SGLT2i in Type 2 Diabetes patients on metformin and sitagliptin compared to direct intensification with insulin in the United Kingdom
For UK T2D patients not at goal on metformin and sitagliptin therapy, treatment intensification with SGLT2i prior to NPH insulin is cost‐neutral or cost‐effective compared to immediate NPH insulin intensification (Diabetes, Obesity and Metabolism)
- 1
- 2
- 3
- …
- 173
- Next Page »
Glycosmedia is also available as an App: